DonaldKStricklandJr.MD

Oncology • Cordova, TN

Independent consult, early phase oncology trials

Join to view full profile

Dr. Strickland is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Strickland's full profile

Already have an account?

Office
9190 Beaver Valley Ln
Cordova, TN 38018
Phone+1 901-309-2572

Education & Training

Duke University HospitalFellowship, Pediatric Hematology/Oncology, 1991 - 1994
Children’s Mercy HospitalResidency, Pediatrics, 1988 - 1991
University of Missouri Kansas City School of MedicineClass of 1988

Certifications & Licensure

TN State Medical License 1997 - 2025
AR State Medical License 2001 - 2004
NC State Medical License 1991 - 1999

Clinical Trials

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Start of enrollment: 2014 Feb 01
Completed
Phase 1
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors Start of enrollment: 2014 Feb 01
Completed
Phase 1
Study of the Glutaminase Inhibitor CB-839 in Leukemia Start of enrollment: 2014 Mar 01
Completed
Phase 1

Publications & Presentations

PubMed

139 citations
Late Effects of Treatment in Survivors of Childhood Acute Myeloid Leukemia
Wing Leung, Melissa M. Hudson, Donald K. Strickland, Sean Phipps, Deo Kumar Srivastava
Journal of Clinical Oncology. 2000-09-18
354 citations
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Charles M. Rudin, M. Catherine Pietanza, Todd M. Bauer, Neal Ready, Daniel Morgensztern
The Lancet. Oncology. 2017-01-01
62 citations
The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children's Research Hospital hepatitis C seropositive cohort.
Sharon. M. Castellino, Shelly Lensing, Caroline A. Riely, Shesh N. Rai, Rene Davila
Blood. 2004-04-01

Abstracts/Posters

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Na¥ve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive...
Donald K. Strickland, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Grant Support

Hepatitis C In Childhood Cancer SurvivorsNational Cancer Institute1999